Loading clinical trials...
Loading clinical trials...
A Randomized, Double-blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Escalating Doses of SAN-300 in Patients With Active Rheumatoid Arthritis With Inadequate Response to Disease-Modifying Anti-rheumatic Drug(s).
Conditions
Interventions
SAN-300 0.5 mg/kg QW
SAN-300 1.0 mg/kg QW
+4 more
Locations
12
United States
Santarus Clinical Investigational Site 1012
Phoenix, Arizona, United States
Santarus Clinical Investigational Site 1004
El Cajon, California, United States
Santarus Clinical Investigational Site 1008
Los Angeles, California, United States
Santarus Clinical Investigational Site 1011
San Leandro, California, United States
Santarus Clinical Investigational Site 1013
Brandon, Florida, United States
Santarus Clinical Investigational Site 1003
Palm Harbor, Florida, United States
Start Date
December 1, 2013
Primary Completion Date
February 23, 2017
Completion Date
March 23, 2017
Last Updated
June 21, 2021
NCT06329401
NCT06647069
NCT07484243
NCT06841562
NCT07268326
NCT06599658
Lead Sponsor
Bausch Health Americas, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions